Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $48.75

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $48.75.

ANAB has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday. UBS Group reaffirmed a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. JPMorgan Chase & Co. lifted their price target on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. HC Wainwright lifted their price target on AnaptysBio from $38.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 price target on shares of AnaptysBio in a report on Tuesday, September 30th.

Institutional Investors Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its holdings in AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Osaic Holdings Inc. raised its holdings in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in AnaptysBio during the first quarter worth approximately $113,000.

AnaptysBio Stock Down 1.3%

Shares of NASDAQ ANAB opened at $31.37 on Wednesday. The firm’s 50-day moving average price is $22.98 and its two-hundred day moving average price is $22.30. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $36.54. The stock has a market capitalization of $878.36 million, a P/E ratio of -7.00 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. The company had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. As a group, equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.